nodes	percent_of_prediction	percent_of_DWPC	metapath
Penicillamine—Interstitial pneumonia—Sorafenib—liver cancer	0.0362	0.037	CcSEcCtD
Penicillamine—Nephrotic syndrome—Sorafenib—liver cancer	0.0362	0.037	CcSEcCtD
Penicillamine—Interstitial lung disease—Sorafenib—liver cancer	0.0247	0.0253	CcSEcCtD
Penicillamine—Leukaemia—Epirubicin—liver cancer	0.024	0.0245	CcSEcCtD
Penicillamine—L-Cysteine—GOT1—liver cancer	0.0233	1	CrCbGaD
Penicillamine—Leukaemia—Doxorubicin—liver cancer	0.0222	0.0227	CcSEcCtD
Penicillamine—Proteinuria—Sorafenib—liver cancer	0.0199	0.0204	CcSEcCtD
Penicillamine—Protein urine present—Sorafenib—liver cancer	0.0196	0.0201	CcSEcCtD
Penicillamine—Glossitis—Sorafenib—liver cancer	0.019	0.0194	CcSEcCtD
Penicillamine—Neuropathy—Sorafenib—liver cancer	0.0164	0.0168	CcSEcCtD
Penicillamine—Mouth ulceration—Sorafenib—liver cancer	0.0158	0.0162	CcSEcCtD
Penicillamine—Hepatic function abnormal—Sorafenib—liver cancer	0.0145	0.0149	CcSEcCtD
Penicillamine—Hepatic failure—Sorafenib—liver cancer	0.0141	0.0145	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Sorafenib—liver cancer	0.0134	0.0138	CcSEcCtD
Penicillamine—Abdominal pain upper—Sorafenib—liver cancer	0.0116	0.0119	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.0114	0.0117	CcSEcCtD
Penicillamine—Pancreatitis—Sorafenib—liver cancer	0.0107	0.011	CcSEcCtD
Penicillamine—Eruption—Epirubicin—liver cancer	0.0105	0.0107	CcSEcCtD
Penicillamine—Optic neuritis—Epirubicin—liver cancer	0.0105	0.0107	CcSEcCtD
Penicillamine—Thrombocytosis—Epirubicin—liver cancer	0.0104	0.0106	CcSEcCtD
Penicillamine—Eruption—Doxorubicin—liver cancer	0.00971	0.00995	CcSEcCtD
Penicillamine—Optic neuritis—Doxorubicin—liver cancer	0.00971	0.00995	CcSEcCtD
Penicillamine—Thrombocytosis—Doxorubicin—liver cancer	0.00961	0.00984	CcSEcCtD
Penicillamine—Renal failure—Sorafenib—liver cancer	0.00961	0.00984	CcSEcCtD
Penicillamine—Neuropathy peripheral—Sorafenib—liver cancer	0.00958	0.00981	CcSEcCtD
Penicillamine—Bone marrow depression—Epirubicin—liver cancer	0.00957	0.00979	CcSEcCtD
Penicillamine—Stomatitis—Sorafenib—liver cancer	0.00953	0.00975	CcSEcCtD
Penicillamine—Hepatobiliary disease—Sorafenib—liver cancer	0.00924	0.00946	CcSEcCtD
Penicillamine—Bone marrow depression—Doxorubicin—liver cancer	0.00885	0.00906	CcSEcCtD
Penicillamine—Haemoglobin—Sorafenib—liver cancer	0.00882	0.00903	CcSEcCtD
Penicillamine—Haemorrhage—Sorafenib—liver cancer	0.00877	0.00898	CcSEcCtD
Penicillamine—Urinary tract disorder—Sorafenib—liver cancer	0.00866	0.00887	CcSEcCtD
Penicillamine—Urethral disorder—Sorafenib—liver cancer	0.0086	0.00881	CcSEcCtD
Penicillamine—Rash erythematous—Epirubicin—liver cancer	0.00843	0.00863	CcSEcCtD
Penicillamine—Tinnitus—Sorafenib—liver cancer	0.00818	0.00838	CcSEcCtD
Penicillamine—Ageusia—Epirubicin—liver cancer	0.00797	0.00816	CcSEcCtD
Penicillamine—Angiopathy—Sorafenib—liver cancer	0.00796	0.00815	CcSEcCtD
Penicillamine—Rash erythematous—Doxorubicin—liver cancer	0.0078	0.00799	CcSEcCtD
Penicillamine—Alopecia—Sorafenib—liver cancer	0.00775	0.00794	CcSEcCtD
Penicillamine—Mental disorder—Sorafenib—liver cancer	0.00769	0.00787	CcSEcCtD
Penicillamine—Dysgeusia—Sorafenib—liver cancer	0.00748	0.00766	CcSEcCtD
Penicillamine—Extravasation—Epirubicin—liver cancer	0.0074	0.00758	CcSEcCtD
Penicillamine—Ageusia—Doxorubicin—liver cancer	0.00737	0.00755	CcSEcCtD
Penicillamine—Anaemia—Sorafenib—liver cancer	0.00706	0.00723	CcSEcCtD
Penicillamine—Glossitis—Epirubicin—liver cancer	0.00701	0.00717	CcSEcCtD
Penicillamine—Extravasation—Doxorubicin—liver cancer	0.00685	0.00701	CcSEcCtD
Penicillamine—Leukopenia—Sorafenib—liver cancer	0.00684	0.007	CcSEcCtD
Penicillamine—Arthralgia—Sorafenib—liver cancer	0.0065	0.00666	CcSEcCtD
Penicillamine—Glossitis—Doxorubicin—liver cancer	0.00648	0.00664	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00646	0.00661	CcSEcCtD
Penicillamine—Thrombocytopenia—Sorafenib—liver cancer	0.0061	0.00625	CcSEcCtD
Penicillamine—Neuropathy—Epirubicin—liver cancer	0.00606	0.00621	CcSEcCtD
Penicillamine—Aplastic anaemia—Epirubicin—liver cancer	0.00606	0.00621	CcSEcCtD
Penicillamine—Skin disorder—Sorafenib—liver cancer	0.00605	0.0062	CcSEcCtD
Penicillamine—Anorexia—Sorafenib—liver cancer	0.00594	0.00608	CcSEcCtD
Penicillamine—Mouth ulceration—Epirubicin—liver cancer	0.00584	0.00598	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00568	0.00582	CcSEcCtD
Penicillamine—Neuropathy—Doxorubicin—liver cancer	0.00561	0.00574	CcSEcCtD
Penicillamine—Aplastic anaemia—Doxorubicin—liver cancer	0.00561	0.00574	CcSEcCtD
Penicillamine—Lymphadenopathy—Epirubicin—liver cancer	0.00549	0.00563	CcSEcCtD
Penicillamine—Decreased appetite—Sorafenib—liver cancer	0.00542	0.00555	CcSEcCtD
Penicillamine—Thrombophlebitis—Epirubicin—liver cancer	0.00541	0.00554	CcSEcCtD
Penicillamine—Mouth ulceration—Doxorubicin—liver cancer	0.0054	0.00553	CcSEcCtD
Penicillamine—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00539	0.00552	CcSEcCtD
Penicillamine—Hepatic function abnormal—Epirubicin—liver cancer	0.00536	0.00549	CcSEcCtD
Penicillamine—Hepatic failure—Epirubicin—liver cancer	0.00522	0.00534	CcSEcCtD
Penicillamine—Lymphadenopathy—Doxorubicin—liver cancer	0.00508	0.0052	CcSEcCtD
Penicillamine—Thrombophlebitis—Doxorubicin—liver cancer	0.00501	0.00513	CcSEcCtD
Penicillamine—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00499	0.00511	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Epirubicin—liver cancer	0.00497	0.00509	CcSEcCtD
Penicillamine—Hepatic function abnormal—Doxorubicin—liver cancer	0.00496	0.00508	CcSEcCtD
Penicillamine—Urticaria—Sorafenib—liver cancer	0.00495	0.00507	CcSEcCtD
Penicillamine—Body temperature increased—Sorafenib—liver cancer	0.00493	0.00505	CcSEcCtD
Penicillamine—Hepatic failure—Doxorubicin—liver cancer	0.00483	0.00494	CcSEcCtD
Penicillamine—Hypoglycaemia—Epirubicin—liver cancer	0.0048	0.00492	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Doxorubicin—liver cancer	0.0046	0.00471	CcSEcCtD
Penicillamine—Hypersensitivity—Sorafenib—liver cancer	0.00459	0.0047	CcSEcCtD
Penicillamine—Hypoglycaemia—Doxorubicin—liver cancer	0.00444	0.00455	CcSEcCtD
Penicillamine—Abdominal pain upper—Epirubicin—liver cancer	0.00428	0.00438	CcSEcCtD
Penicillamine—Diarrhoea—Sorafenib—liver cancer	0.00427	0.00437	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00422	0.00432	CcSEcCtD
Penicillamine—Muscular weakness—Epirubicin—liver cancer	0.00413	0.00423	CcSEcCtD
Penicillamine—Asthma—Epirubicin—liver cancer	0.00405	0.00415	CcSEcCtD
Penicillamine—Eosinophilia—Epirubicin—liver cancer	0.00401	0.00411	CcSEcCtD
Penicillamine—Pancreatitis—Epirubicin—liver cancer	0.00397	0.00407	CcSEcCtD
Penicillamine—Vomiting—Sorafenib—liver cancer	0.00396	0.00406	CcSEcCtD
Penicillamine—Abdominal pain upper—Doxorubicin—liver cancer	0.00396	0.00406	CcSEcCtD
Penicillamine—Rash—Sorafenib—liver cancer	0.00393	0.00402	CcSEcCtD
Penicillamine—Dermatitis—Sorafenib—liver cancer	0.00393	0.00402	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00391	0.004	CcSEcCtD
Penicillamine—Pancytopenia—Epirubicin—liver cancer	0.00385	0.00394	CcSEcCtD
Penicillamine—Muscular weakness—Doxorubicin—liver cancer	0.00383	0.00392	CcSEcCtD
Penicillamine—Asthma—Doxorubicin—liver cancer	0.00375	0.00384	CcSEcCtD
Penicillamine—Eosinophilia—Doxorubicin—liver cancer	0.00371	0.0038	CcSEcCtD
Penicillamine—Nausea—Sorafenib—liver cancer	0.0037	0.00379	CcSEcCtD
Penicillamine—Pancreatitis—Doxorubicin—liver cancer	0.00368	0.00376	CcSEcCtD
Penicillamine—Pancytopenia—Doxorubicin—liver cancer	0.00356	0.00364	CcSEcCtD
Penicillamine—Renal failure—Epirubicin—liver cancer	0.00355	0.00364	CcSEcCtD
Penicillamine—Neuropathy peripheral—Epirubicin—liver cancer	0.00354	0.00363	CcSEcCtD
Penicillamine—Stomatitis—Epirubicin—liver cancer	0.00352	0.00361	CcSEcCtD
Penicillamine—Haematuria—Epirubicin—liver cancer	0.00344	0.00353	CcSEcCtD
Penicillamine—Hepatobiliary disease—Epirubicin—liver cancer	0.00342	0.0035	CcSEcCtD
Penicillamine—Agranulocytosis—Epirubicin—liver cancer	0.00337	0.00345	CcSEcCtD
Penicillamine—Renal failure—Doxorubicin—liver cancer	0.00329	0.00336	CcSEcCtD
Penicillamine—Neuropathy peripheral—Doxorubicin—liver cancer	0.00328	0.00335	CcSEcCtD
Penicillamine—Haemoglobin—Epirubicin—liver cancer	0.00326	0.00334	CcSEcCtD
Penicillamine—Stomatitis—Doxorubicin—liver cancer	0.00326	0.00334	CcSEcCtD
Penicillamine—Haemorrhage—Epirubicin—liver cancer	0.00324	0.00332	CcSEcCtD
Penicillamine—Urinary tract disorder—Epirubicin—liver cancer	0.0032	0.00328	CcSEcCtD
Penicillamine—Haematuria—Doxorubicin—liver cancer	0.00319	0.00326	CcSEcCtD
Penicillamine—Urethral disorder—Epirubicin—liver cancer	0.00318	0.00325	CcSEcCtD
Penicillamine—Hepatobiliary disease—Doxorubicin—liver cancer	0.00316	0.00324	CcSEcCtD
Penicillamine—Agranulocytosis—Doxorubicin—liver cancer	0.00312	0.00319	CcSEcCtD
Penicillamine—Tinnitus—Epirubicin—liver cancer	0.00302	0.0031	CcSEcCtD
Penicillamine—Haemoglobin—Doxorubicin—liver cancer	0.00302	0.00309	CcSEcCtD
Penicillamine—Haemorrhage—Doxorubicin—liver cancer	0.003	0.00307	CcSEcCtD
Penicillamine—Urinary tract disorder—Doxorubicin—liver cancer	0.00296	0.00303	CcSEcCtD
Penicillamine—Angiopathy—Epirubicin—liver cancer	0.00294	0.00301	CcSEcCtD
Penicillamine—Urethral disorder—Doxorubicin—liver cancer	0.00294	0.00301	CcSEcCtD
Penicillamine—Alopecia—Epirubicin—liver cancer	0.00287	0.00293	CcSEcCtD
Penicillamine—Mental disorder—Epirubicin—liver cancer	0.00284	0.00291	CcSEcCtD
Penicillamine—Tinnitus—Doxorubicin—liver cancer	0.0028	0.00286	CcSEcCtD
Penicillamine—Dysgeusia—Epirubicin—liver cancer	0.00276	0.00283	CcSEcCtD
Penicillamine—Angiopathy—Doxorubicin—liver cancer	0.00272	0.00279	CcSEcCtD
Penicillamine—Alopecia—Doxorubicin—liver cancer	0.00265	0.00271	CcSEcCtD
Penicillamine—Mental disorder—Doxorubicin—liver cancer	0.00263	0.00269	CcSEcCtD
Penicillamine—Anaemia—Epirubicin—liver cancer	0.00261	0.00267	CcSEcCtD
Penicillamine—Agitation—Epirubicin—liver cancer	0.00259	0.00266	CcSEcCtD
Penicillamine—Dysgeusia—Doxorubicin—liver cancer	0.00256	0.00262	CcSEcCtD
Penicillamine—Leukopenia—Epirubicin—liver cancer	0.00253	0.00259	CcSEcCtD
Penicillamine—Anaemia—Doxorubicin—liver cancer	0.00241	0.00247	CcSEcCtD
Penicillamine—Arthralgia—Epirubicin—liver cancer	0.0024	0.00246	CcSEcCtD
Penicillamine—Agitation—Doxorubicin—liver cancer	0.0024	0.00246	CcSEcCtD
Penicillamine—Anxiety—Epirubicin—liver cancer	0.00239	0.00245	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00239	0.00244	CcSEcCtD
Penicillamine—Leukopenia—Doxorubicin—liver cancer	0.00234	0.00239	CcSEcCtD
Penicillamine—Thrombocytopenia—Epirubicin—liver cancer	0.00226	0.00231	CcSEcCtD
Penicillamine—Skin disorder—Epirubicin—liver cancer	0.00224	0.00229	CcSEcCtD
Penicillamine—Arthralgia—Doxorubicin—liver cancer	0.00222	0.00228	CcSEcCtD
Penicillamine—Anxiety—Doxorubicin—liver cancer	0.00222	0.00227	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00221	0.00226	CcSEcCtD
Penicillamine—Anorexia—Epirubicin—liver cancer	0.0022	0.00225	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.0021	0.00215	CcSEcCtD
Penicillamine—Thrombocytopenia—Doxorubicin—liver cancer	0.00209	0.00214	CcSEcCtD
Penicillamine—Skin disorder—Doxorubicin—liver cancer	0.00207	0.00212	CcSEcCtD
Penicillamine—Anorexia—Doxorubicin—liver cancer	0.00203	0.00208	CcSEcCtD
Penicillamine—Decreased appetite—Epirubicin—liver cancer	0.002	0.00205	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00194	0.00199	CcSEcCtD
Penicillamine—Decreased appetite—Doxorubicin—liver cancer	0.00185	0.0019	CcSEcCtD
Penicillamine—Urticaria—Epirubicin—liver cancer	0.00183	0.00187	CcSEcCtD
Penicillamine—Body temperature increased—Epirubicin—liver cancer	0.00182	0.00186	CcSEcCtD
Penicillamine—Hypersensitivity—Epirubicin—liver cancer	0.0017	0.00174	CcSEcCtD
Penicillamine—Urticaria—Doxorubicin—liver cancer	0.00169	0.00173	CcSEcCtD
Penicillamine—Body temperature increased—Doxorubicin—liver cancer	0.00169	0.00173	CcSEcCtD
Penicillamine—Diarrhoea—Epirubicin—liver cancer	0.00158	0.00161	CcSEcCtD
Penicillamine—Hypersensitivity—Doxorubicin—liver cancer	0.00157	0.00161	CcSEcCtD
Penicillamine—Vomiting—Epirubicin—liver cancer	0.00146	0.0015	CcSEcCtD
Penicillamine—Diarrhoea—Doxorubicin—liver cancer	0.00146	0.00149	CcSEcCtD
Penicillamine—Rash—Epirubicin—liver cancer	0.00145	0.00149	CcSEcCtD
Penicillamine—Dermatitis—Epirubicin—liver cancer	0.00145	0.00149	CcSEcCtD
Penicillamine—Nausea—Epirubicin—liver cancer	0.00137	0.0014	CcSEcCtD
Penicillamine—Vomiting—Doxorubicin—liver cancer	0.00136	0.00139	CcSEcCtD
Penicillamine—Rash—Doxorubicin—liver cancer	0.00134	0.00138	CcSEcCtD
Penicillamine—Dermatitis—Doxorubicin—liver cancer	0.00134	0.00137	CcSEcCtD
Penicillamine—Nausea—Doxorubicin—liver cancer	0.00127	0.0013	CcSEcCtD
